# A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

> **NCT01525394** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 52 (actual)

## Conditions studied

- Refractory Solid Tumors
- Lymphomas

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Moxifloxacin 400 mg
- **DRUG:** Placebos (matched to 4 mg and 10 mg lenvatinib capsules).

## Key facts

- **NCT ID:** NCT01525394
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-08
- **Final completion:** —
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01525394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01525394, "A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01525394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*